Retrospective investigation of tacrolimus combined with an anti-tumor necrosis factorα antibody as remission induction therapy for refractory ulcerative colitis: Efficacy, safety, and relapse rate.
combined therapy with tacrolimus and an anti‐TNFα antibody
refractory ulcerative colitis
remission induction therapy
Journal
JGH open : an open access journal of gastroenterology and hepatology
ISSN: 2397-9070
Titre abrégé: JGH Open
Pays: Australia
ID NLM: 101730833
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
28
11
2018
revised:
21
03
2019
accepted:
17
04
2019
entrez:
14
12
2019
pubmed:
14
12
2019
medline:
14
12
2019
Statut:
epublish
Résumé
Combined therapy with tacrolimus (TAC) and an anti-tumor necrosis factorα (TNFα) antibody is used to induce remission in ulcerative colitis (UC) patients who have not responded to monotherapy with either drug. We evaluated the efficacy and safety of combined therapy, as well as the relapse rate. Combined therapy was performed to induce remission in UC patients showing an inadequate response to monotherapy with TAC or an anti-TNFα antibody. The following items were assessed retrospectively: (i) clinical characteristics, (ii) the remission induction rate, (iii) the relapse rate, and (iv) adverse events. Combined therapy induced remission in 7 of the 12 patients (58.3%). There were no significant differences in clinical characteristics between the patients with and without the successful induction of remission. However, the number of female patients tended to be higher in the remission group than in the nonremission group. The remission group also showed trends of a lower clinical activity index (Lichtiger index; CAI) on admission and before combined therapy and a lower total dose of prednisolone during hospitalization. The 1-year relapse rate was 33.3%. Adverse events due to combined therapy included renal impairment ( Combined therapy was effective in more than half of the patients with refractory UC who had not responded to monotherapy. Our findings suggest that combination therapy may be a new, third option for the treatment of refractory UC.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Combined therapy with tacrolimus (TAC) and an anti-tumor necrosis factorα (TNFα) antibody is used to induce remission in ulcerative colitis (UC) patients who have not responded to monotherapy with either drug. We evaluated the efficacy and safety of combined therapy, as well as the relapse rate.
METHODS
METHODS
Combined therapy was performed to induce remission in UC patients showing an inadequate response to monotherapy with TAC or an anti-TNFα antibody. The following items were assessed retrospectively: (i) clinical characteristics, (ii) the remission induction rate, (iii) the relapse rate, and (iv) adverse events.
RESULTS
RESULTS
Combined therapy induced remission in 7 of the 12 patients (58.3%). There were no significant differences in clinical characteristics between the patients with and without the successful induction of remission. However, the number of female patients tended to be higher in the remission group than in the nonremission group. The remission group also showed trends of a lower clinical activity index (Lichtiger index; CAI) on admission and before combined therapy and a lower total dose of prednisolone during hospitalization. The 1-year relapse rate was 33.3%. Adverse events due to combined therapy included renal impairment (
CONCLUSIONS
CONCLUSIONS
Combined therapy was effective in more than half of the patients with refractory UC who had not responded to monotherapy. Our findings suggest that combination therapy may be a new, third option for the treatment of refractory UC.
Identifiants
pubmed: 31832554
doi: 10.1002/jgh3.12197
pii: JGH312197
pmc: PMC6891029
doi:
Types de publication
Journal Article
Langues
eng
Pagination
525-531Informations de copyright
© 2019 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Surg Clin North Am. 2013 Feb;93(1):107-43
pubmed: 23177068
Br J Surg. 2010 Mar;97(3):404-9
pubmed: 20101648
Gastroenterology. 2013 Nov;145(5):987-95
pubmed: 23891974
N Engl J Med. 1994 Jun 30;330(26):1841-5
pubmed: 8196726
Clin Gastroenterol Hepatol. 2008 Oct;6(10):1112-6
pubmed: 18928936
Int J Clin Pharmacol Ther. 2016 Feb;54(2):125-8
pubmed: 26754306
Inflamm Bowel Dis. 2018 May 18;24(6):1298-1306
pubmed: 29688413
J Antibiot (Tokyo). 1987 Sep;40(9):1256-65
pubmed: 2445722
Mod Rheumatol. 2018 Jan;28(1):48-57
pubmed: 28649878
J Crohns Colitis. 2017 Jul 1;11(7):769-784
pubmed: 28513805
Gastroenterology. 2011 Oct;141(4):1194-201
pubmed: 21723220
Aliment Pharmacol Ther. 2010 May;31(9):1036-41
pubmed: 20175769
J Crohns Colitis. 2015 Jan;9(1):4-25
pubmed: 25304060
Rheumatol Int. 2009 Sep;29(11):1287-91
pubmed: 19153737
Gut. 2006 Sep;55(9):1255-62
pubmed: 16484504
J Crohns Colitis. 2016 Apr;10(4):484-94
pubmed: 26645641
Inflamm Bowel Dis. 2018 Apr 23;24(5):989-996
pubmed: 29688472
Clin Gastroenterol Hepatol. 2019 Feb;17(3):486-493
pubmed: 29751166
N Engl J Med. 2005 Dec 8;353(23):2462-76
pubmed: 16339095
Inflamm Bowel Dis. 2015 Jul;21(7):1683-94
pubmed: 25839775
N Engl J Med. 1987 Dec 24;317(26):1625-9
pubmed: 3317057
Dig Liver Dis. 2018 Aug;50(8):812-819
pubmed: 29625907